Global Cord Blood Corporation
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Ting Zheng
- Full Time Employees
- 1,202
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- Bank of China Tower Central Hong Kong
- IPO Date
- Jan 25, 2007
- CIK
- 0001467808
- Website
- globalcordbloodcorp.com
- Similar Companies
- Business
- Global Cord Blood Corporation, a Cayman Islands-incorporated holding company listed on the OTC market (ticker: CORBF), operates as China's largest umbilical cord blood banking provider through its subsidiaries; it offers comprehensive umbilical cord blood storage services encompassing cord blood collection from newborn infants, laboratory testing, hematopoietic stem cell processing, cryopreservation storage, and matching services for donated units to transplant patients. The company provides these services to subscribers for processing and annual storage fees, as well as public donation processing and delivery of matching units; it maintains GMP-compliant clean processing laboratories, national-standard testing and cryopreservation facilities, and computerized security systems across multiple provinces including Beijing, Guangdong, Zhejiang, and partial ownership in Shandong. Founded in 2003 as China Cord Blood Corporation and renamed Global Cord Blood Corporation in 2018 to reflect international ambitions, it is headquartered at 48th Floor, Bank of China Tower, 1 Garden Road, Central, Hong Kong, with principal operations in the People's Republic of China serving regions accounting for nearly three-quarters of national births. In April 2022, the company announced a $1 billion acquisition of Cellenkos Inc., a U.S.-based biotech firm developing T-regulatory cell therapies from cord blood, involving $664 million cash and 125 million new shares; this transaction, linked to majority shareholder Golden Meditech, triggered shareholder dilution concerns, NYSE delisting in 2023, and ongoing provisional liquidation proceedings under Joint Provisional Liquidators appointed by the Cayman Islands Grand Court since September 2022. As of December 2025, the liquidators continue restructuring efforts, with their fourteenth report submitted on December 1 detailing progress amid disputes over the share register and professional fees.
Company News
Is Winter About to Show Off? Vail Resorts Announces 2026/27 Opening Dates as Super El Niño Builds Anticipation for Great Powder
Kidde Enhances Carbon Monoxide (CO) Detection with Advanced Low-Level Alarms
Global Cord Blood (NYSE:CO) Share Price Passes Above Two Hundred Day Moving Average – Here’s What Happened
Real Yields, Oil, Conflict Scenarios
CO, CORBF DEADLINE: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Global Cord Blood Corporation Investors to Secure Counsel Before Important June 24 Deadline in Securities Class Action – CO, CORBF
CO, CORBF Deadline: CO, CORBF Investors Have the Opportunity to Lead Global Cord Blood Corporation Securities Fraud Lawsuit
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Global Cord
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Global Cord Blood Corporation Investors to Secure Counsel Before Important June 24 Deadline in Securities Class Action – CO, CORBF
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Global Cord Blood Corporation Investors to Secure Counsel Before Important June 24 Deadline in Securities Class Action – CO, CORBF
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Global Cord Blood Corporation (CORBF)
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Global Cord Blood Corporation of Class Action Lawsuit and Upcoming Deadlines – CORBF
ROSEN, A LEADING LAW FIRM, Encourages Global Cord Blood Corporation Investors to Secure Counsel Before Important June 24 Deadline in Securities Class Action – CO, CORBF
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Global Cord
Rosen Law Firm Urges Global Cord Blood Corporation (NYSE: CO) (OTC: CORBF) Stockholders With Large Losses to Contact the Firm for Information About Their Rights
Global Cord Blood Corporation Investors: Looming Deadline in Class action lawsuit filed on behalf of investors; the Portnoy Law Firm
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Global Cord Blood Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - CO, CORBF
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Global Cord Blood Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – CO, CORBF
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Global Cord Blood Corporation (CORBF)
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Global Cord
CORBF STOCKHOLDERS: Contact Robbins LLP for Information About the Pending Lead Plaintiff Deadline in the Global Cord Blood Corporation Class Action